Efficacy of continuous epidural infusion of hydromorphone combined with ropivacaine versus ropivacaine alone for treating acute/subacut severe herpetic neuralgia

Efficacy of continuous epidural infusion of hydromorphone combined with ropivacaine versus ropivacaine alone for treating acute/subacut severe herpetic neuralgia: a randomized, double-blinded, controlled trail

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062269

Enrollment

Unknown

Registered

2022-07-31

Start date

2022-07-29

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster

Interventions

Experimental group:continuous epidural infusion of Hydromorphone and ropivacaine

Control group:continuous epidural infusion of ropivacaine

Eligibility

Sex/Gender

All

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Have a clear history of herpes zoster and post-herpetic scar or pigmentation in the T3 -- T12 spinal innervation area. 2. Patients with visualanalogue scale (VAS) >= 7 points at admission and still unable to relieve pain with oral drugs. 3. Aged 50-85 years, the course of disease is within 1 month. 4. Able to adhere to the whole treatment and follow-up. 5. All patients received regular antiviral and nutritional neurotherapy before inclusion.

Exclusion criteria

Exclusion criteria: 1. Skin infection and abnormal coagulation at the puncture site, and severe spinal deformity could not complete the puncture. 2. Patients with other intractable pain and unidentifiable pain related to shingles. 3. Patients with severe heart, lung, renal insufficiency and malignancy, mental illness or opioid allergy and abuse. 4. Unable to fully understand the VAS rating scale.

Design outcomes

Primary

Measure	Time frame
visual analogue scale score;number of bursts of pain;30-day pregabalin dosage;	—

Secondary

Measure	Time frame
adverse reactions;	—

Countries

China

Contacts

Public ContactQing Shuai

Yibin First People's Hospital

genqing642367@163.com+86 13795809884

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026